奥沙利铂联合希罗达治疗晚期胃癌的临床观察

目的：观察奥沙利铂联合希罗达方案治疗晚期胃癌的临床疗效及不良反应。方法：36例晚期胃癌患者，给予该方案化疗：奥沙利铂100mg／m^2d1；希罗达1000mg／m^2每日两次口服，d1-14；每21天为1周期，至少完成2个周期。评价客观疗效和不良反应。结果：全组36例均可评价疗效，其中完全缓解（CR）2例，部分缓解（PR）13例，稳定（SD）11例，进展（PD）10例，总有效率（CR＋PR）41．7％。中位肿瘤进展时间（mITP）8．9个月，中位生存时间（MST）为10．2个月。不良反应主要是骨髓抑制，胃肠道反应及外周神经毒性。结论：FOLFOX4方案治疗晚期胃癌的近期疗效较好，不良反应可以耐受。

Clinical study on patients with advanced gastric cancer treated with oxaliplatin plus xeloda

Objective：To evaluate the efficacy and toxicity of oxaliplatin combined with Xeloda in the treatment of advanced gastric cancer. Methods： Thirty six patients with advanced gastric cancer were treated with chemotherapy： oxaliplatin 100 mg/m^2 ,ivgtt,dI ;Xeloda 1000mg/m^2 Bid,d1-14. 21days for one cycle. All patients received two cycles at least. Efficacy and toxicity were evaluated. Results： All the 36 patients were evaluated,2 patients achieved complete remission （ CR = 5.6% ） , 17 patients partial remission （ PR = 36.1% ）, 13 patients stable disease （ SD = 30.6% ） ,7 patients progressire disease （ PD = 27.8% ）. The total response rate was 41.7%. The median time to progression （mTTP） was 8.9 months. The median survival time （MST） was 10.2 months, major toxicity included leucopenia, nausea, vomiting and neurosensory abnormity. Conclusion： Regimen of oxaliplatin combined with Xeloda is effective and tolerable in advanced gastric cancer.